The ribosomopathies comprise a group of disorders characterized by aberrant ribosome biogenesis and function, resulting in specific disease phenotypes. 1 The 5q-syndrome, the most distinct of all the myelodysplastic syndromes (MDS), 2 is now recognized as a ribosomopathy. The CD34 þ cells of patients with the 5q-syndrome show haploinsufficiency of the ribosomal protein gene RPS14, 3, 4 which maps to the commonly deleted region (CDR) on chromosome 5q. 2 It has been demonstrated that p53 activation secondary to RPS14 haploinsufficiency has an important role in the development of anemia in the 5q-syndrome. 5, 6 Haploinsufficiency of RPS14 in the 5q-syndrome is associated with a block in the processing of pre-ribosomal RNA 4 and deregulation of ribosomal-and translation-related genes. 7 Defective ribosome biogenesis can result in a reduction in the efficiency of mRNA translation 4, 8 and cultured erythroblasts from patients with the 5q-syndrome, 8 and the ribosomopathy Schwachman-Diamond syndrome, 9 exhibit impaired mRNA translation. Therefore, this defect in translation may represent a potential therapeutic target in the 5q-syndrome and other ribosomopathies.
Several lines of evidence indicate that the use of the amino acid L-leucine, a translation enhancer, may have some efficacy in the treatment of certain ribosomopathies. A patient with DiamondBlackfan anemia (DBA) showed a marked improvement in anemia and became transfusion-independent following L-leucine therapy. 10 Indeed, the addition of L-leucine to cultured lymphocytes obtained from patients with DBA was shown to result in an increase in translational efficiency. 11 Recently, DBA and del(5q) MDS have been modeled in zebrafish using antisense morpholinos to knockdown rps19 and rps14, respectively. 12 The treatment of the zebrafish models of DBA and del(5q) MDS with L-leucine resulted in an improvement in the hemoglobinization, red cell numbers and developmental defects. 12 Similarly, the treatment of Rps19-deficient mice with L-leucine has been shown to result in an improvement in the anemia, with an increase in hemoglobin concentration and the number of erythrocytes. 13 In a recent study, we have shown that L-leucine treatment of cultured human erythroblasts derived from CD34 þ bone marrow cells with RPS14 knockdown and from MDS patients with del(5q) results in an increase in the cell proliferation, erythroid differentiation and mRNA translation. 8 These studies suggest that L-leucine may have therapeutic effects in certain ribosomopathies by stimulating mRNA translation and cell growth.
L-leucine is a branched chain amino acid that is not only a substrate for protein synthesis but also serves as a nutrient that regulates protein metabolism through activation of mTOR (mammalian Target of Rapamycin) signaling. 1 The mTOR signaling pathway integrates signals from nutrients, growth factors and cellular energy status to regulate cell growth and proliferation.
14 The overall signaling network is divided into two major branches, which correspond to two distinct multiprotein complexes, mTORC1 and mTORC2. mTORC1 controls cell growth through mRNA translation and there is evidence to suggest that the amino acid leucine is required for activation of mTORC1. 1, 15 Activated mTORC1 regulates protein synthesis through phosphorylation of its key downstream targets S6K1 and 4EBP1. Phosphorylated S6K1 and 4EBP1 enhance the activation of translation initiation factors that regulate mRNA binding to the ribosomal complex, and several other substrates associated with the ribosome, and thus modulate mRNA translation. 1, 14 The phosphorylation status of 4EBP1 and S6K1 is widely used to assess mTORC1 activity. 1 Recently, L-leucine has been shown to activate the mTORC1 pathway via phosphorylation of S6K1 in the zebrafish models of DBA and 5q-MDS. 12 However, to date there is no data linking activation of mTOR pathway with L-leucine in human RPS14-deficient hematopoietic cells.
In this study, we sought to illuminate the mode of action of L-leucine in the enhancement of cell growth and differentiation in human erythroid progenitor cells haploinsufficient for the ribosomal protein RPS14. Firstly, we have determined the effects of L-leucine on the phosphorylation levels of the downstream targets of mTORC1, 4EBP1 and S6K1, in RPS14-deficient erythroblasts generated using small hairpin RNA (shRNA) technology. Secondly, we have investigated the effects of L-leucine on the phosphorylation levels of 4EBP1 and S6K1 in the cultured erythroblasts of patients with del(5q) MDS.
To study mTOR signaling in an in vitro cellular model of the 5q-syndrome, RPS14-deficient erythroblasts were generated by lentiviral shRNA silencing in CD34 þ cells from healthy controls cultured as previously described 8 (see Supplementary Methods). The expression levels of RPS14 were decreased by B50% in the cells expressing shRNAs (Supplementary Figure S1) . Using sandwich ELISA and flow cytometry, we showed that L-leucine treatment resulted in a significant increase in the phosphorylation level of S6K1 in erythroblasts with RPS14 knockdown (Figures 1a  and b , and western blot in Supplementary Figure S2) . Similarly, we observed a significant increase in the phosphorylation level of 4EBP1 in the cells with RPS14 knockdown following L-leucine treatment (Figures 1a and b) . No significant difference was observed in the phosphorylation levels of S6K1 and 4EBP1 in erythroblasts expressing a scramble shRNA control (Figures 1a  and b) . In order to investigate the specificity of the effects of L-leucine, we next evaluated the effects of the inactive D-leucine isomer on phosphorylation of 4EBP1 and S6K1. Unlike L-leucine, the optical isomer (enantiomer) D-leucine is not incorporated into proteins during translation and therefore does not act as a translation enhancer. 12 In our study, no significant change in the phosphorylation levels of 4EBP1 and S6K1 was observed in the erythroblasts with RPS14 knockdown following treatment with D-leucine (Figures 1c and d) .
To confirm that phosphorylation of 4EBP1 and S6K1 occurs via activation of the mTORC1 pathway by L-leucine, we treated RPS14-deficient erythroblasts with L-leucine in the presence or absence of rapamycin, a specific inhibitor of mTORC1. The treatment of erythroblasts with RPS14 knockdown with L-leucine in the presence of rapamycin did not result in an increase in the phosphorylation levels of 4EBP1 and S6K1, in contrast to the erythroblasts treated with L-leucine but in the absence of rapamycin (Figures 1a and b) . These data indicate that L-leucine activates the mTORC1 pathway in RPS14-deficient erythroblasts. Interestingly, activation of the mTORC1 pathway via a rapamycin-sensitive phosphorylation of S6K1 has been recently described in zebrafish models of DBA and 5q-MDS following treatment with L-leucine. 12 Accepted article preview online 22 January 2013; advance online publication, 12 February 2013 Letters to the Editor Figure 1 . L-leucine activates the mTORC1 pathway in RPS14-deficient cells resulting in an increase in the phosphorylation levels of 4EBP1 and S6K1. Bone marrow CD34 þ cells from healthy controls with RPS14 knockdown (two different shRNA sequences, indicated as 'sh41' and 'sh44') were harvested after treatment with L-leucine only, rapamycin only, L-leucine and rapamycin or D-leucine only (at day 11 of the erythroid culture). The phosphorylation levels of 4EBP1 and S6K1 were measured by sandwich ELISA and flow cytometry. Both assays involved antibodies specific to the phosphorylated form of the proteins. In the ELISA assays, the optical density values obtained were normalized to the amount of protein (mg) loaded for each sample. In flow cytometric analysis, the phosphorylation levels of 4EBP1 and S6K1 are represented by the median fluorescence intensity of fluorochrome. (a, b) Phosphorylation levels of 4EBP1 and S6K1 measured by sandwich ELISA (a) and flow cytometry (b) after treatment with L-leucine only, rapamycin only or both L-leucine and rapamycin (n ¼ 6). (c, d) Phosphorylation levels of 4EBP1 and S6K1 measured by sandwich ELISA (c) and flow cytometry (d) after treatment with L-leucine or D-leucine (n ¼ 4). Bar graphs show mean ± s.e.m., (ns ¼ not significant, *P ¼ o0.05, **P ¼ o0.01 and ***P ¼ o0.001, paired t-test).
Next, we evaluated the effects of L-leucine on mTORC1 signaling in cultured erythroblasts obtained from the bone marrow cells of three MDS patients with del(5q) as the sole karyotypic abnormality. The cultured erythroblasts from MDS patients with del(5q) showed reduced phosphorylation levels of S6K1 and 4EBP1 compared with cultured erythroblasts of healthy controls (Figures 2a and b) , suggesting that the del(5q) is associated with a decrease in mTORC1 signaling in the MDS patients. Consistent with our data on erythroblasts from healthy controls with RPS14 knockdown, the cultured erythroblasts from three MDS patients with del(5q) demonstrated an increase in the level of phosphorylation of S6K1 following treatment with L-leucine (Figures 2a-c) . A slight increase in the phosphorylation level of 4EBP1 was observed in the cells of MDS patients with del(5q) treated with L-leucine (Figures 2a and b) . The inactive D-leucine isomer showed no effect on the phosphorylation levels of S6K1 and 4EBP1 in the erythroblasts from the three MDS patients with del(5q) and from healthy controls (Figures 2a and b) . We then studied the effects of L-leucine on erythroid differentiation, by staining for the erythroid cell surface markers CD71 and CD235a. An increase in early (CD71 þ CD235a À ) and intermediate (CD71 Figure S3) . Consistent with our previous report, 8 these data show that L-leucine treatment is associated with an improvement in erythroid differentiation in cultured cells obtained from MDS patients with del(5q). Our data supports the hypothesis that treatment with L-leucine ameliorates the phenotype associated with RPS14 deficiency in cultured erythroblasts from MDS patients with del(5q), through activation of mTORC1 signaling.
We have previously shown that RPS14-deficient erythroblasts and cultured erythroblasts from MDS patients with the del(5q), show reduced levels of mRNA translation, and that the translation enhancer L-leucine increased the erythroid differentiation, cell proliferation and translation efficiency of these cells. 8 In this present study, we demonstrate a rapamycin-sensitive increase in the phosphorylation levels of S6K1 and 4EBP1 in L-leucine treated RPS14-deficient erythroblasts. Similarly, we have shown an increase in phosphorylation of S6K1 in cultured erythroblasts from MDS patients with del(5q). These data shed light on the mode of action of L-leucine through activation of mTOR signaling pathway in RPS14-deficient human erythroid cells. Our studies suggest that L-leucine treatment may lead to an amelioration of the erythroid defect observed in del(5q) MDS and support the evaluation of L-leucine as a potential therapeutic agent in the treatment of this patient group. Polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis (PMF) are clonal myeloproliferative neoplasms (MPNs) with a high frequency of the 1849G4T mutation in JAK2 referred to as JAK2V617F. How this mutation gives rise to different clinical phenotypes with diverse prognoses is unknown. Expression of JAK2V617F in genetically modified mice correlates with disease features. 1 Some data in humans support this notion. [2] [3] [4] Other mutations, including those in JAK2 exon-12, TET2, MPL, EZH2 and ASXL1 occurs at varying frequency 5 in persons with MPNs Whether these mutations correlate with disease phenotype and/or prognosis is unknown.
Another possible explanation for the diversity of MPNs associated with JAK2V617F is the genetic background on which the mutation occurs. One potential relevant factor is the specific constitutional JAK2 haplotype, designated 46/1 or GGCC, which is correlated with JAK2V617F in cases of European descent. [6] [7] [8] [9] We recently reported that Chinese with PMF have different clinical features than that of Europeans with PMF despite a similar frequency of JAK2V617F. 10 We sought to determine whether the JAK2 46/1 haplotype was also associated with JAK2V617F in Chinese and whether differences in the frequency of this genotype might explain different clinical phenotypes of Chinese and Europeans with PMF and other MPNs.
To accomplish this, we assessed JAK2V617F allele burden and genotyped three 46/1 tagged SNPs in 635 Chinese with PV, ET or PMF (Supplementary Table 1 
